Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants
American Journal of Physiology-Cell Physiology · 01.06.2026 · 330 (6) · C1788-C1799
DOI: 10.1152/ajpcell.00239.2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.06.2026. Verfasst von Rahul U Chandrappa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States. Hauptthemen laut MEDLINE: Shaw Potassium Channels, Gain of Function Mutation, Potassium Channel Blockers, Drug Discovery. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, HHS | National Institutes of Health (NIH), VUMC | Vanderbilt Cancer Center (VICC).
Abstract (Originalsprache)
This study identifies the first structurally diverse collection of small-molecule inhibitors of Kv3.1 potassium channels, highlighting VU426 as a moderately potent, state-dependent inactivator. Notably, VU426 displays enhanced potency against multiple pathogenic gain-of-function Kv3.1 mutants, revealing a mechanism-based strategy for selectively targeting disease-associated channel variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States.
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
- High Throughput Screening Core Facility, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee, United States.
ORCID-Profile: Rahul U Chandrappa, Jerod S Denton
Förderung
- NIMH NIH HHS
- HHS | National Institutes of Health (NIH)
- VUMC | Vanderbilt Cancer Center (VICC)
- HHS | NIH | National Institute of Mental Health (NIMH)
Zitieren
APA
Chandrappa, R. U., Satpute Janve, V., Days, E. L., & Denton, J. S. (2026). Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants. American Journal of Physiology-Cell Physiology, 330(6), C1788-C1799. https://doi.org/10.1152/ajpcell.00239.2026
Vancouver
Chandrappa RU, Satpute Janve V, Days EL, Denton JS. Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants. American Journal of Physiology-Cell Physiology. 2026;330(6):C1788-C1799. doi:10.1152/ajpcell.00239.2026
BibTeX
@article{Chandrappa2026,
author = {Chandrappa, Rahul U and Satpute Janve, Vaishali and Days, Emily L and Denton, Jerod S},
title = {Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
volume = {330},
number = {6},
pages = {C1788--C1799},
doi = {10.1152/ajpcell.00239.2026}
}
EUVIMED